Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Purpose Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [ 68 Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-1...
Gespeichert in:
| Veröffentlicht in: | Molecular imaging and biology 2015-08, Vol.17 (4), p.575-584 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 584 |
|---|---|
| container_issue | 4 |
| container_start_page | 575 |
| container_title | Molecular imaging and biology |
| container_volume | 17 |
| creator | Dietlein, Markus Kobe, Carsten Kuhnert, Georg Stockter, Simone Fischer, Thomas Schomäcker, Klaus Schmidt, Matthias Dietlein, Felix Zlatopolskiy, Boris D. Krapf, Philipp Richarz, Raphael Neubauer, Stephan Drzezga, Alexander Neumaier, Bernd |
| description | Purpose
Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [
68
Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production amount, and image resolution. [
18
F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomography (PET) imaging that has been recently introduced. In the current study, we aimed to compare [
68
Ga]Ga-PSMA-HBED-CC and [
18
F]DCFPyL for clinical use in biochemically relapsed prostate cancer.
Procedures
In 14 selected patients with PSA relapse of prostate cancer, [
18
F]DCFPyL PET/X-ray computed tomography (CT) was performed in addition to [
68
Ga]Ga-PSMA-HBED-CC PET/CT. A systematic comparison was carried out between results obtained with both tracers with regard to the number of detected PSMA-positive lesions, the standardized uptake value (SUV)
max
and the lesion to background ratios.
Results
All suspicious lesions identified by [
68
Ga]Ga-PSMA-HBED-CC were also detected with [
18
F]DCFPyL. In three patients, additional lesions were observed using [
18
F]DCFPyL PET/CT. The mean SUV
max
in the concordant [
18
F]DCFPyL PSMA-positive lesions was significantly higher as compared to [
68
Ga]Ga-PSMA-HBED-CC (14.5
vs.
12.2,
p
= 0.028,
n
= 15). The mean tumor to background ratios (
n
= 15) were significantly higher for [
18
F]DCFPyL compared to [
68
Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as reference organs (
p
= 0.006,
p
= 0.002,
p
= 0.008), but no significant differences were found using the liver (
p
= 0.167) or the mediastinum (
p
= 0.363) as reference organs.
Conclusion
[
18
F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [
18
F]DCFPyL represents a highly promising alternative to [
68
Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer. |
| doi_str_mv | 10.1007/s11307-015-0866-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4493776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1709177797</sourcerecordid><originalsourceid>FETCH-LOGICAL-c573t-6eee8dea3286bfbd9961557e1650b636665dc31ade79982e64bc8cbb0c8cf2933</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhiMEoqXwAFyQJS5cDDN2YscXpDbd3VZaRATlVFWWkzjbVIm92FlQ3x6XLVVB4uKxPN_8npk_y14jvEcA-SEicpAUsKBQCkHhSXaIpQDKANjTdC-4oCg4O8hexHgDgBIZf54dMAHIc6kOs1D5aWvCEL0jvieXWC6vTqtlfbsmxnXkUpQrc7UytP766ZienSxOaVWR3gfy-6FeXJDzyWwGtyGDI7WZB-vmSH4O8zX5YkezjbYjdfBxNrMllXGtDS-zZ70Zo311H4-yb8vFRXVG159X59XxmraF5DMV1tqys4azUjR90yklsCikRVFAI7gQouhajqazUqmSWZE3bdk2DaSzZ4rzo-zjXne7aybbtamzYEa9DcNkwq32ZtB_Z9xwrTf-h85zxaUUSeDdvUDw33c2znoaYmvH0Tjrd1GjBIVSSiUT-vYf9MbvgkvjaRQqLxDyHBOFe6pNG4nB9g_NIOg7R_XeUZ0c1XeOakg1bx5P8VDxx8IEsD0QU8ptbHj09X9VfwFzdak0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1694510441</pqid></control><display><type>article</type><title>Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Dietlein, Markus ; Kobe, Carsten ; Kuhnert, Georg ; Stockter, Simone ; Fischer, Thomas ; Schomäcker, Klaus ; Schmidt, Matthias ; Dietlein, Felix ; Zlatopolskiy, Boris D. ; Krapf, Philipp ; Richarz, Raphael ; Neubauer, Stephan ; Drzezga, Alexander ; Neumaier, Bernd</creator><creatorcontrib>Dietlein, Markus ; Kobe, Carsten ; Kuhnert, Georg ; Stockter, Simone ; Fischer, Thomas ; Schomäcker, Klaus ; Schmidt, Matthias ; Dietlein, Felix ; Zlatopolskiy, Boris D. ; Krapf, Philipp ; Richarz, Raphael ; Neubauer, Stephan ; Drzezga, Alexander ; Neumaier, Bernd</creatorcontrib><description>Purpose
Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [
68
Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production amount, and image resolution. [
18
F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomography (PET) imaging that has been recently introduced. In the current study, we aimed to compare [
68
Ga]Ga-PSMA-HBED-CC and [
18
F]DCFPyL for clinical use in biochemically relapsed prostate cancer.
Procedures
In 14 selected patients with PSA relapse of prostate cancer, [
18
F]DCFPyL PET/X-ray computed tomography (CT) was performed in addition to [
68
Ga]Ga-PSMA-HBED-CC PET/CT. A systematic comparison was carried out between results obtained with both tracers with regard to the number of detected PSMA-positive lesions, the standardized uptake value (SUV)
max
and the lesion to background ratios.
Results
All suspicious lesions identified by [
68
Ga]Ga-PSMA-HBED-CC were also detected with [
18
F]DCFPyL. In three patients, additional lesions were observed using [
18
F]DCFPyL PET/CT. The mean SUV
max
in the concordant [
18
F]DCFPyL PSMA-positive lesions was significantly higher as compared to [
68
Ga]Ga-PSMA-HBED-CC (14.5
vs.
12.2,
p
= 0.028,
n
= 15). The mean tumor to background ratios (
n
= 15) were significantly higher for [
18
F]DCFPyL compared to [
68
Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as reference organs (
p
= 0.006,
p
= 0.002,
p
= 0.008), but no significant differences were found using the liver (
p
= 0.167) or the mediastinum (
p
= 0.363) as reference organs.
Conclusion
[
18
F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [
18
F]DCFPyL represents a highly promising alternative to [
68
Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.</description><identifier>ISSN: 1536-1632</identifier><identifier>EISSN: 1860-2002</identifier><identifier>DOI: 10.1007/s11307-015-0866-0</identifier><identifier>PMID: 26013479</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Aged, 80 and over ; Edetic Acid - analogs & derivatives ; Edetic Acid - pharmacokinetics ; Edetic Acid - therapeutic use ; Humans ; Imaging ; Liver - metabolism ; Lysine - analogs & derivatives ; Lysine - pharmacokinetics ; Lysine - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oligopeptides - pharmacokinetics ; Oligopeptides - therapeutic use ; Positron-Emission Tomography - methods ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - pathology ; Radiology ; Radiopharmaceuticals - pharmacokinetics ; Radiopharmaceuticals - therapeutic use ; Recurrence ; Research Article ; Urea - analogs & derivatives ; Urea - pharmacokinetics ; Urea - therapeutic use</subject><ispartof>Molecular imaging and biology, 2015-08, Vol.17 (4), p.575-584</ispartof><rights>The Author(s) 2015</rights><rights>Academy of Molecular Imaging and Society for Molecular Imaging 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c573t-6eee8dea3286bfbd9961557e1650b636665dc31ade79982e64bc8cbb0c8cf2933</citedby><cites>FETCH-LOGICAL-c573t-6eee8dea3286bfbd9961557e1650b636665dc31ade79982e64bc8cbb0c8cf2933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11307-015-0866-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11307-015-0866-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26013479$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dietlein, Markus</creatorcontrib><creatorcontrib>Kobe, Carsten</creatorcontrib><creatorcontrib>Kuhnert, Georg</creatorcontrib><creatorcontrib>Stockter, Simone</creatorcontrib><creatorcontrib>Fischer, Thomas</creatorcontrib><creatorcontrib>Schomäcker, Klaus</creatorcontrib><creatorcontrib>Schmidt, Matthias</creatorcontrib><creatorcontrib>Dietlein, Felix</creatorcontrib><creatorcontrib>Zlatopolskiy, Boris D.</creatorcontrib><creatorcontrib>Krapf, Philipp</creatorcontrib><creatorcontrib>Richarz, Raphael</creatorcontrib><creatorcontrib>Neubauer, Stephan</creatorcontrib><creatorcontrib>Drzezga, Alexander</creatorcontrib><creatorcontrib>Neumaier, Bernd</creatorcontrib><title>Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer</title><title>Molecular imaging and biology</title><addtitle>Mol Imaging Biol</addtitle><addtitle>Mol Imaging Biol</addtitle><description>Purpose
Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [
68
Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production amount, and image resolution. [
18
F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomography (PET) imaging that has been recently introduced. In the current study, we aimed to compare [
68
Ga]Ga-PSMA-HBED-CC and [
18
F]DCFPyL for clinical use in biochemically relapsed prostate cancer.
Procedures
In 14 selected patients with PSA relapse of prostate cancer, [
18
F]DCFPyL PET/X-ray computed tomography (CT) was performed in addition to [
68
Ga]Ga-PSMA-HBED-CC PET/CT. A systematic comparison was carried out between results obtained with both tracers with regard to the number of detected PSMA-positive lesions, the standardized uptake value (SUV)
max
and the lesion to background ratios.
Results
All suspicious lesions identified by [
68
Ga]Ga-PSMA-HBED-CC were also detected with [
18
F]DCFPyL. In three patients, additional lesions were observed using [
18
F]DCFPyL PET/CT. The mean SUV
max
in the concordant [
18
F]DCFPyL PSMA-positive lesions was significantly higher as compared to [
68
Ga]Ga-PSMA-HBED-CC (14.5
vs.
12.2,
p
= 0.028,
n
= 15). The mean tumor to background ratios (
n
= 15) were significantly higher for [
18
F]DCFPyL compared to [
68
Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as reference organs (
p
= 0.006,
p
= 0.002,
p
= 0.008), but no significant differences were found using the liver (
p
= 0.167) or the mediastinum (
p
= 0.363) as reference organs.
Conclusion
[
18
F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [
18
F]DCFPyL represents a highly promising alternative to [
68
Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Edetic Acid - analogs & derivatives</subject><subject>Edetic Acid - pharmacokinetics</subject><subject>Edetic Acid - therapeutic use</subject><subject>Humans</subject><subject>Imaging</subject><subject>Liver - metabolism</subject><subject>Lysine - analogs & derivatives</subject><subject>Lysine - pharmacokinetics</subject><subject>Lysine - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oligopeptides - pharmacokinetics</subject><subject>Oligopeptides - therapeutic use</subject><subject>Positron-Emission Tomography - methods</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Radiology</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Recurrence</subject><subject>Research Article</subject><subject>Urea - analogs & derivatives</subject><subject>Urea - pharmacokinetics</subject><subject>Urea - therapeutic use</subject><issn>1536-1632</issn><issn>1860-2002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kcFu1DAQhiMEoqXwAFyQJS5cDDN2YscXpDbd3VZaRATlVFWWkzjbVIm92FlQ3x6XLVVB4uKxPN_8npk_y14jvEcA-SEicpAUsKBQCkHhSXaIpQDKANjTdC-4oCg4O8hexHgDgBIZf54dMAHIc6kOs1D5aWvCEL0jvieXWC6vTqtlfbsmxnXkUpQrc7UytP766ZienSxOaVWR3gfy-6FeXJDzyWwGtyGDI7WZB-vmSH4O8zX5YkezjbYjdfBxNrMllXGtDS-zZ70Zo311H4-yb8vFRXVG159X59XxmraF5DMV1tqys4azUjR90yklsCikRVFAI7gQouhajqazUqmSWZE3bdk2DaSzZ4rzo-zjXne7aybbtamzYEa9DcNkwq32ZtB_Z9xwrTf-h85zxaUUSeDdvUDw33c2znoaYmvH0Tjrd1GjBIVSSiUT-vYf9MbvgkvjaRQqLxDyHBOFe6pNG4nB9g_NIOg7R_XeUZ0c1XeOakg1bx5P8VDxx8IEsD0QU8ptbHj09X9VfwFzdak0</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Dietlein, Markus</creator><creator>Kobe, Carsten</creator><creator>Kuhnert, Georg</creator><creator>Stockter, Simone</creator><creator>Fischer, Thomas</creator><creator>Schomäcker, Klaus</creator><creator>Schmidt, Matthias</creator><creator>Dietlein, Felix</creator><creator>Zlatopolskiy, Boris D.</creator><creator>Krapf, Philipp</creator><creator>Richarz, Raphael</creator><creator>Neubauer, Stephan</creator><creator>Drzezga, Alexander</creator><creator>Neumaier, Bernd</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>5PM</scope></search><sort><creationdate>20150801</creationdate><title>Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer</title><author>Dietlein, Markus ; Kobe, Carsten ; Kuhnert, Georg ; Stockter, Simone ; Fischer, Thomas ; Schomäcker, Klaus ; Schmidt, Matthias ; Dietlein, Felix ; Zlatopolskiy, Boris D. ; Krapf, Philipp ; Richarz, Raphael ; Neubauer, Stephan ; Drzezga, Alexander ; Neumaier, Bernd</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c573t-6eee8dea3286bfbd9961557e1650b636665dc31ade79982e64bc8cbb0c8cf2933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Edetic Acid - analogs & derivatives</topic><topic>Edetic Acid - pharmacokinetics</topic><topic>Edetic Acid - therapeutic use</topic><topic>Humans</topic><topic>Imaging</topic><topic>Liver - metabolism</topic><topic>Lysine - analogs & derivatives</topic><topic>Lysine - pharmacokinetics</topic><topic>Lysine - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oligopeptides - pharmacokinetics</topic><topic>Oligopeptides - therapeutic use</topic><topic>Positron-Emission Tomography - methods</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Radiology</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Recurrence</topic><topic>Research Article</topic><topic>Urea - analogs & derivatives</topic><topic>Urea - pharmacokinetics</topic><topic>Urea - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dietlein, Markus</creatorcontrib><creatorcontrib>Kobe, Carsten</creatorcontrib><creatorcontrib>Kuhnert, Georg</creatorcontrib><creatorcontrib>Stockter, Simone</creatorcontrib><creatorcontrib>Fischer, Thomas</creatorcontrib><creatorcontrib>Schomäcker, Klaus</creatorcontrib><creatorcontrib>Schmidt, Matthias</creatorcontrib><creatorcontrib>Dietlein, Felix</creatorcontrib><creatorcontrib>Zlatopolskiy, Boris D.</creatorcontrib><creatorcontrib>Krapf, Philipp</creatorcontrib><creatorcontrib>Richarz, Raphael</creatorcontrib><creatorcontrib>Neubauer, Stephan</creatorcontrib><creatorcontrib>Drzezga, Alexander</creatorcontrib><creatorcontrib>Neumaier, Bernd</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular imaging and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dietlein, Markus</au><au>Kobe, Carsten</au><au>Kuhnert, Georg</au><au>Stockter, Simone</au><au>Fischer, Thomas</au><au>Schomäcker, Klaus</au><au>Schmidt, Matthias</au><au>Dietlein, Felix</au><au>Zlatopolskiy, Boris D.</au><au>Krapf, Philipp</au><au>Richarz, Raphael</au><au>Neubauer, Stephan</au><au>Drzezga, Alexander</au><au>Neumaier, Bernd</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer</atitle><jtitle>Molecular imaging and biology</jtitle><stitle>Mol Imaging Biol</stitle><addtitle>Mol Imaging Biol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>17</volume><issue>4</issue><spage>575</spage><epage>584</epage><pages>575-584</pages><issn>1536-1632</issn><eissn>1860-2002</eissn><abstract>Purpose
Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [
68
Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production amount, and image resolution. [
18
F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomography (PET) imaging that has been recently introduced. In the current study, we aimed to compare [
68
Ga]Ga-PSMA-HBED-CC and [
18
F]DCFPyL for clinical use in biochemically relapsed prostate cancer.
Procedures
In 14 selected patients with PSA relapse of prostate cancer, [
18
F]DCFPyL PET/X-ray computed tomography (CT) was performed in addition to [
68
Ga]Ga-PSMA-HBED-CC PET/CT. A systematic comparison was carried out between results obtained with both tracers with regard to the number of detected PSMA-positive lesions, the standardized uptake value (SUV)
max
and the lesion to background ratios.
Results
All suspicious lesions identified by [
68
Ga]Ga-PSMA-HBED-CC were also detected with [
18
F]DCFPyL. In three patients, additional lesions were observed using [
18
F]DCFPyL PET/CT. The mean SUV
max
in the concordant [
18
F]DCFPyL PSMA-positive lesions was significantly higher as compared to [
68
Ga]Ga-PSMA-HBED-CC (14.5
vs.
12.2,
p
= 0.028,
n
= 15). The mean tumor to background ratios (
n
= 15) were significantly higher for [
18
F]DCFPyL compared to [
68
Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as reference organs (
p
= 0.006,
p
= 0.002,
p
= 0.008), but no significant differences were found using the liver (
p
= 0.167) or the mediastinum (
p
= 0.363) as reference organs.
Conclusion
[
18
F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [
18
F]DCFPyL represents a highly promising alternative to [
68
Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>26013479</pmid><doi>10.1007/s11307-015-0866-0</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-1632 |
| ispartof | Molecular imaging and biology, 2015-08, Vol.17 (4), p.575-584 |
| issn | 1536-1632 1860-2002 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4493776 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Aged, 80 and over Edetic Acid - analogs & derivatives Edetic Acid - pharmacokinetics Edetic Acid - therapeutic use Humans Imaging Liver - metabolism Lysine - analogs & derivatives Lysine - pharmacokinetics Lysine - therapeutic use Male Medicine Medicine & Public Health Middle Aged Oligopeptides - pharmacokinetics Oligopeptides - therapeutic use Positron-Emission Tomography - methods Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Radiology Radiopharmaceuticals - pharmacokinetics Radiopharmaceuticals - therapeutic use Recurrence Research Article Urea - analogs & derivatives Urea - pharmacokinetics Urea - therapeutic use |
| title | Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A04%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20%5B18F%5DDCFPyL%20and%20%5B68Ga%5DGa-PSMA-HBED-CC%20for%20PSMA-PET%20Imaging%20in%20Patients%20with%20Relapsed%20Prostate%20Cancer&rft.jtitle=Molecular%20imaging%20and%20biology&rft.au=Dietlein,%20Markus&rft.date=2015-08-01&rft.volume=17&rft.issue=4&rft.spage=575&rft.epage=584&rft.pages=575-584&rft.issn=1536-1632&rft.eissn=1860-2002&rft_id=info:doi/10.1007/s11307-015-0866-0&rft_dat=%3Cproquest_pubme%3E1709177797%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1694510441&rft_id=info:pmid/26013479&rfr_iscdi=true |